Anzeige
Mehr »
Dienstag, 10.02.2026 - Börsentäglich über 12.000 News
Breaking News: Pacifica meldet neue hochgradige Entdeckung und genau deshalb kann der Markt das nicht ignorieren
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
139 Leser
Artikel bewerten:
(0)

Cryo-Save Group N.V.: Cryo-Save to launch Cryo-Lip in the US

Cryo-Save Group N.V. (Euronext: CRYO, 'Cryo-Save' or 'the Group'), Europe's leading stem cell bank,today announced that it intends to launch Cryo-Lip in the United States in 2011, after the successful introduction of the service in Europe during 2010.

Cryo-Save is one of the first in the world that offers cryostorage of adult mesenchymal stem cells from fatty tissue for use by patients undergoing a surgical procedure.

Cryo-Save is currently looking for partners to roll out this service in the United States.

Cryo-Lip has been launched in Spain and Italy in June 2010 and has since also been introduced in Greece, Bulgaria, Hungary and Cyprus. It will also be made available in the Netherlands this month.

The Cryo-Lip service has been expanded thanks to new clinical developments, which means it will be available to a much larger segment of patients.

Dr Henk Snyman, Managing Director for Cryo-Lip explained:

"Apart from the cryostorage of adult stem cells for later medical use, we can now also release back to plastic surgeons the adipose tissue itself (Processed LipoAspirate or PLA Liquid) for clinical applications such as lipofilling. In addition, we have just successfully completed a pilot project, validating the collection of adult mesenchymal stem cells from patients undergoing surgical procedures such as elective caesarian sections, general surgical or orthopedic operations.".

Cryo-Save has developed a novel cryopreservation process specifically for adipose tissue, which has been submitted as an international patent. The Company is an accredited tissue bank for the cryopreservation and storage of fatty tissue.

Fat is the richest source of adult mesenchymal stem cells (called ASCs or adipose-derived stem cells when harvested from fat) in the human body and readily accessible (Gimble 2007).  Cryo-Lip requires less than 50 ml of tissue, which can easily be obtained. ASCs are regarded as the building blocks of regenerative medicine (Yoshimura 2008), a concept supported by recent publications with significantly positive results in patients with acute and chronic cardiac ischemia.

The interest from the plastic surgery community has been very high with positive acceptance of this groundbreaking opportunity for their patients. To date the company has registered and trained close to 100 plastic and reconstructive surgeons as Cryo-Lip Providers who are now able to offer the service to their patients.

Dr. Jorge Planas, an internationally renowned Plastic and Reconstructive Surgeon in Barcelona and the Chairman of the Cryo-Lip Advisory Panel, commented:

"We are receiving positive feedback from both physicians and patients. I am convinced that the cryopreservation of adipose tissue and adult stem cells creates a major benefit for many and will be widely used".

 Arnoud van Tulder, the Cryo-Save CEO, added:

 "Being the first in this new market segment represents an important strategic advantage for our company.  We are aiming for global leadership and are actively investigating our options with regard to the introduction in the USA, the biggest commercial market in the world".

Websites: www.cryo-lip.com (http://www.cryo-lip.com/) / www.cryo-save.com (http://www.cryo-save.com)



Enquiries:

Cryo-Lip +41 555 330 122

Henk Snyman, MD, Managing Director info@cryo-lip.com (mailto:info@cryo-lip.com)

Cryo-Save Group + 31 (0) 575 548 998

Arnoud van Tulder, Chief Executive Officer

Daniel Stewart & Company plc + 44 (0) 20 7776 6550

Chris Theis

College Hill (UK) + 44 (0) 20 7457 2020

Rozi Morris/Adrian Duffield

SPJ Financiele Communicatie Amstelveen (Netherlands) +31 (0)20-6478181

Kees Jongsma/Leon Melens

Free footage is availabla on www.videobankonline.com (http://www.videobankonline.com/).

About Cryo-Save

With more than 140,000 samples saved, Cryo-Save is the leading stem cell bank in Europe and one of the fastest growing in the world. Driven by its international business strategy, Cryo-Save is now represented in 40 countries on three continents with state-of-the-art processing facilities in Belgium, Germany, Dubai, India and France (in progress). Cryo-Save Group is listed on Euronext Amsterdam.

click here for press release in PDF (http://hugin.info/143308/R/1472908/409379.pdf)

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Cryo-Save Group N.V. via Thomson Reuters ONE


HUG#1472908


© 2010 GlobeNewswire (Europe)
Favoritenwechsel
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.